Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness.

@article{Hofer2001TrypanosomaBC,
  title={Trypanosoma brucei CTP synthetase: a target for the treatment of African sleeping sickness.},
  author={Anders Hofer and Dietmar Steverding and Andrei Chabes and Reto Brun and Lars Thelander},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2001},
  volume={98 11},
  pages={6412-6}
}
The drugs in clinical use against African sleeping sickness are toxic, costly, or inefficient. We show that Trypanosoma brucei, which causes this disease, has very low levels of CTP, which are due to a limited capacity for de novo synthesis and the lack of salvage pathways. The CTP synthetase inhibitors 6-diazo-5-oxo-l-norleucine (DON) and alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin) reduced the parasite CTP levels even further and inhibited trypanosome proliferation in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Bioinformatics and Drug Discovery

Current topics in medicinal chemistry • 2017
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…